Pune-based drug maker Emcure Pharmaceuticals would be launching a generic version of a breast cancer drug Eribulin, at 40% cost less than the original drug.
According to reports, Emcure’s ‘eribilin’ is the first generically similar version of the innovator drug Halaven ‘eribulin’, sold by Japanese drugmaker Eisai Pharmaceuticals to treat metastatic breast cancer.
Sainath Iyer, Emcure’s President, Emerging and Super Speciality Business, said that eribulin was on the list of 42 cancer drugs whose trade margins were capped by the government recently at 30%.
Emcure’s eribilin is priced at ₹19,500 per vial, compared to Eisai’s eribulin at ₹31,000 per vial. The total treatment cost for four cycles can cost upto ₹3 lakh for a patient. The drug’s production is presently outsourced, but as volumes increase, the price could see a revision downwards, said Iyer.
“Generic Eribulin is a research landmark,” said Mukund Gurjar, Emcure’s Chief Scientific Officer, in terms of producing both the active pharmaceutical ingredient and the formulation.